Maplight Therapeutics

This study is testing the long-term safety and effectiveness of an investigational drug called ML-007C-MA in adults with schizophrenia. About 500 participants will take the drug for up to 52 weeks to see how well it is tolerated and if it helps control symptoms. The goal is to fi…

This study looks at the long-term safety of an experimental drug, ML007C-MA, for people with Alzheimer's disease who experience hallucinations and delusions. It is an open-label extension, meaning all participants will receive the drug for up to 52 weeks. The goal is to see if th…

This study tests an experimental oral medication, ML-007C-MA, against a placebo in 300 adults hospitalized for a sudden worsening of schizophrenia symptoms. The goal is to see if the drug safely reduces psychosis severity, measured by a standard symptom scale. Participants must b…

This study tests an experimental drug, ML-007C-MA, to see if it can reduce hallucinations and delusions in people with Alzheimer's disease. About 300 participants aged 55 to 90 will receive either the drug or a placebo. The goal is to improve quality of life by easing these distr…